Jessica Hinson
Family · El Paso, TXNPI 1417229220
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 532 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 532 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- AstraZeneca$1K
- AbbVie$756
- GSK$736
- Pfizer$719
- plus $3K from 29 others
What the payments were for
- Food & beverage$9,815100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,775 |
| Lilly USA, LLC | 140 | $1,609 |
| AstraZeneca | 26 | $1,239 |
| AbbVie(2 entities) | 55 | $756 |
| GSK | 48 | $736 |
| Pfizer | 50 | $719 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $400 |
| Amgen(2 entities) | 23 | $345 |
| Abbott | 6 | $338 |
| Boehringer Ingelheim | 14 | $294 |
| Sanofi-aventis U.S. LLC | 8 | $186 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $184 |
| Inspire Medical Systems, Inc. | 2 | $160 |
| Mayne Pharma Commercial LLC | 1 | $145 |
| Novartis | 6 | $144 |
| Corcept Therapeutics | 5 | $138 |
| Exact Sciences | 6 | $97 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| Johnson & Johnson | 3 | $62 |
| Genentech USA, Inc. | 6 | $49 |
| Astellas Pharma US Inc | 2 | $46 |
| Dexcom, Inc. | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Sanofi | 1 | $28 |
| Vertex | 1 | $28 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Exeltis, USA Inc. | 1 | $18 |
| Organon | 2 | $17 |
| Tonix Medicines, Inc. | 1 | $17 |
| Biogen | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$393
- BREZTRI$348
- FARXIGA$284
- NURTEC ODT$250
- Wegovy$246
- RYBELSUS$225
- Inspire$147
- FREESTYLE LIBRE 3$134
How this compares
$9,815 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 20 | $23,437 |
| MounjaroTirzepatide | 13 | $18,563 |
| Levothyroxine Sodium | 78 | $1,056 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $481 |
| Rosuvastatin Calcium | 25 | $410 |
| Simvastatin | 37 | $374 |
| Metformin Hcl | 43 | $356 |
| Lisinopril | 45 | $349 |
| Gabapentin | 23 | $345 |
| Metoprolol Succinate | 17 | $327 |
| Atorvastatin Calcium | 25 | $315 |
| Alprazolam | 71 | $272 |
| Montelukast Sodium | 19 | $233 |
| Losartan Potassium | 24 | $216 |
| Amlodipine Besylate | 30 | $165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,775 | $23,43720 claims |
| Lilly USA, LLCMounjaro | $1,609 | $18,56313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in El Paso
- Margarita FavelaEl Paso$73K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.